Zwitterionic Linkers for Radiopharmaceutical Kidney Uptake Control

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current radiopharmaceuticals face issues with unsuitable pharmacokinetics, poor tumor retention, and high retention in healthy tissues, particularly the kidneys, due to the chemical properties of linkers, leading to radiation toxicity and reduced PET imaging contrast.

Innovation Solution

Incorporation of zwitterionic compounds as modular linkers in radiopharmaceuticals to improve pharmacokinetics and reduce non-specific uptake and retention in healthy tissues, using zwitterionic compounds with specific chemical structures to modulate polarity and charge distribution.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If conventional linkers are used in radiopharmaceuticals, then the radiopharmaceutical can be formed and administered, but unsuitable pharmacokinetics and high retention in healthy tissues (particularly kidneys) occur, leading to radiation toxicity

Engineering Contradiction:

ImprovepharmacokineticsVSAvoidradiation toxicity

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by modifying the chemical properties of linkers to incorporate zwitterionic groups with specific charge distributions. This changes the pharmacokinetic parameters of the radiopharmaceutical, reducing renal retention and improving clearance while maintaining target specificity, thereby reducing radiation toxicity to healthy tissues

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent uses composite materials by combining zwitterionic groups with linker structures to create hybrid linkers that exhibit both the structural functionality needed for radiopharmaceutical formation and the charge properties needed to reduce non-specific uptake in healthy tissues, particularly kidneys

Inventive Principle:

Principle #40Composite materials

2Reliability

If conventional linkers are used in radiopharmaceuticals, then the radiopharmaceutical can be formed, but poor tumor retention and low tumor-tissue ratios occur, reducing PET imaging contrast

Engineering Contradiction:

Improvetumor retentionVSAvoidPET imaging contrast

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent modifies the charge distribution parameters of linkers by incorporating zwitterionic groups, which improves tumor retention through enhanced binding characteristics and reduces background signal in healthy tissues. This increases the tumor-tissue ratio and improves PET imaging contrast and measurement precision

Inventive Principle:

Principle #35Parameter changes

3Reliability

If zwitterionic compounds are incorporated as linkers, then pharmacokinetics is improved and healthy-tissue clearance is enhanced, but the chemical structure complexity increases

Engineering Contradiction:

ImprovepharmacokineticsVSAvoidchemical structure

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the chemical parameters of linkers by incorporating zwitterionic groups with specific charge distributions. While this increases structural complexity, it dramatically improves pharmacokinetic parameters including renal clearance, tumor retention, and tumor-tissue ratios, achieving better therapeutic and diagnostic outcomes

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20260069726A1Zwitterionic compounds and uses thereof

Publication Date: 2026.03.12 UNIVERSITY OF SASKATCHEWAN

AI summary

The present application relates to zwitterion compounds of Formula I, to processes of their preparations, to conjugates thereof, to compositions comprising them and to their use in diagnostics and/or therapy. wherein Q is selected from Q1, Q2, Q3, Q4 and Q5: